Intravitreal Devices for the Treatment of Vitreous Inflammation

Table 2

Characteristics of intravitreal devices.

Device	Materials	Active agent	Duration of drug release	Diseases
Nonbiodegradable devices
I-vation	Drug-polymer-coated nonferrous alloy helix (polybutyl methacrylate/polyvinyl alcohol; bravo drug delivery polymer matrix)	Triamcinolone acetonide (1–3 𝜇g/day)	2 years	Investigational: diabetic macular edema phase 2b trial suspended in 2008
Illuvien/medidur	Polyvinyl alcohol (with silicone bioadhesive in low-dose version)	Fluocinolone acetonide (0.59 mg; 0.2–0.5 𝜇g/day)	18–30 months	Investigational: diabetic macular edema (phase 3)
Retisert	Silicone/polyvinyl alcohol	Fluocinolone acetonide (0.59 mg)	Up to 3 years	FDA approved for the treatment of uveitis. Investigational: diabetic macular edema, retinal vein occlusion
Vitrasert	EVA/polyvinyl alcohol	Ganciclovir (4.5 mg)	5 to 8 months	Implantable reservoir system
Biodegradable devices
Ozurdex	Polylactic-co-glycolic acid	Dexamethasone (0.7 mg)	6 months	DA approved for the treatment of macular edema following branch or central retinal vein occlusion. Investigational: diabetic macular edema, uveitis
Surodex	Polylactic-co-glycolic acid, hydroxypropyl methylcellulose	Dexamethasone (60 𝜇g)	7–10 days	Investigational in the USA: postoperative inflammation following cataract surgery (phase 3). Regulatory approvals in Singapore, China, Mexico